Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection

Risk Factors for Acquisition and Clearance of Oral Human Papillomavirus Infection Among HIV-Infected and HIV-Uninfected Adults

(2014) Daniel C. Beachler et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial

(2014) Allan Hildesheim et al.   VACCINE

Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer

(2013) M. Schiffman et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers

(2013) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels

(2013) Ahmedin Jemal et al.   JNCI-Journal of the National Cancer Institute

Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study

(2013) Aimée R Kreimer et al.   LANCET

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

(2013) Rolando Herrero et al.   PLoS One

Rates and Determinants of Oral Human Papillomavirus Infection in Young Men

(2013) Zoe R. Edelstein et al.   SEXUALLY TRANSMITTED DISEASES

Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naive Women in HPV Vaccine Trials

(2012) M. Safaeian et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prevalence of Oral HPV Infection in the United States, 2009-2010

(2012) Maura L. Gillison et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of and Risk Factors for Anal Human Papillomavirus Infection Among Young Healthy Women in Costa Rica

(2012) Felipe A. Castro et al.   JOURNAL OF INFECTIOUS DISEASES

Human Papillomavirus Vaccine Introduction – The First Five Years

(2012) Lauri E. Markowitz et al.   VACCINE

End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

(2011) X Castellsagué et al.   BRITISH JOURNAL OF CANCER

Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal "Pap-Test Equivalent" in High-Risk Populations

(2011) C. Fakhry et al.   Cancer Prevention Research

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18

(2011) A. Szarewski et al.   INTERNATIONAL JOURNAL OF CANCER

Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3

(2011) Ana Cecilia Rodríguez et al.   INTERNATIONAL JOURNAL OF CANCER

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

(2011) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

(2011) Aimée R Kreimer et al.   LANCET ONCOLOGY

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia

(2011) Joel M. Palefsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

(2011) R. Herrero et al.   Cancer Discovery

Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections

(2010) M. Safaeian et al.   JNCI-Journal of the National Cancer Institute

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

(2009) S. K. Kjaer et al.   Cancer Prevention Research

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

(2008) Rolando Herrero et al.   VACCINE